目的 探讨雷公藤多苷联合贝那普利对老年原发性膜性肾小球肾炎患者的临床治疗效果以及治疗后患者机体内炎症各项指标水平的变化情况。方法 收集商洛市中心医院自2015年1月-2017年1月间收治的老年原发性膜性肾小球肾炎患者91例作为研究对象，按照随机数字表法分为研究组47例和对照组44例，对照组患者使用贝那普利进行治疗，同时给予对症治疗，研究组患者在此基础上使用雷公藤多苷进行治疗，观察两组患者的临床效果以及肿瘤坏死因子-α（TNF-α）、超敏C反应蛋白（hs-CRP）以及白介素-6（IL-6）等炎症指标水平的变化情况。结果 研究组患者临床总有效率93.62%，明显高于对照组77.27%，差异具有统计学意义（P<0.05）。治疗前两组患者24 h尿蛋白、尿素氮、肾小球滤过率各项指标比较差异不显著；治疗后以上各指标水平均发生明显改善，同组治疗前后比较差异有统计学意义（P<0.05）；其中研究组改善效果明显优于对照组，差异具有统计学意义（P<0.05）。两组患者治疗前TNF-α、hs-CRP和IL-6等各项炎症因子水平比较差异不大；治疗后两组以上指标均明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；其中研究组患者各项水平显著低于对照组，差异有统计学意义（P<0.05）。结论 雷公藤多苷联合贝那普利能够抑制老年原发性膜性肾小球肾炎患者体内炎症因子的表达，改善肾功能和临床症状，效果显著，可推广使用。

Objective To investigate the clinical therapeutic and efficacy of Tripterygium tilfordii Glycosides for elderly patients with Idiopathic Membranous Glomerulonephritis. And analyze the various indicators of inflammation on patients after the treatment.Methods From January 2010 to January 2017 91 patients with idiopathic membranous glomerulonephritis in our hospital were collected as the research object, and randomly divided into the study group 47 cases and control group 44 cases. Control group were performed the Benner Pury treatment and symptomatic treatment. Based on treatment of Control group, the patients in the study group were given Tripterygium wilfordii glycosides treatment. The clinical effect, tumor necrosis factor α (TNF-α), high sensitive C reactive protein (hs-CRP), interleukin -6 (IL-6) and changes of inflammatory factors were observed in two groups.Results The study group patients clinical total effective rate was 93.62% and significantly higher than the control group (77.27%) (P< 0. 05). there was no significant difference between study group and control group on 24h urine protein, urea nitrogen and glomerular filtration rate before treatment. And the level of each index were significantly improved after treatment, while the study group was obviously better than control group, the difference was statistically significant (P< 0.05). Before treatment two groups of patients has no significant difierence on TNF-α, hs-CRP and IL-6. The level of TNF-α, hs-CRP and IL-6 in two groups were decreased after treatment, and the study group was significantly lower than the control group (P< 0.05).Conclusion Tripterygium glycosides can inhibit the expression of inflammatory factors in elderly patients with Idiopathic Membranous Glomerulonephritis, and improve renal function and clinical symptoms. The clinical therapeutic and efficacy of Tripterygium glycosides is significant, worthy to recommand its clinical use.